Kroon A A, Aengevaeren W R, van der Werf T, Uijen G J, Reiber J H, Bruschke A V, Stalenhoef A F
Department of Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands.
Circulation. 1996 May 15;93(10):1826-35. doi: 10.1161/01.cir.93.10.1826.
Intensive lipid lowering may retard the progression of coronary atherosclerosis. LDL-apheresis has the potential to decrease LDL cholesterol to very low levels. To assess the effect of more aggressive lipid lowering with LDL-apheresis, we set up a randomized study in men with hypercholesterolemia and severe coronary atherosclerosis.
For 2 years, 42 men were treated with either biweekly LDL-apheresis plus medication or medication alone. In both groups a dose of simvistatin of 40 mg per day was administered. Baseline (mean+/-SD) LDL cholesterol was 7.8+/-1.9 mmol x L(-1) and 7.9+/-2.3 mmol x L(-1) in the apheresis and medication groups, respectively. The mean reduction in LDL cholesterol was 63% (to 3.0 mmol x L(-1)) and 47% (to 4.1 mmol x L(-1)), respectively. Primary quantitative coronary angiographic end points were changes in average mean segment diameter and minimal obstruction diameter. No differences between the apheresis and medication groups were found in mean segment diameter (-0.01+/-0.16 mm versus 0.03+/-0.16 mm, respectively) or in minimal obstruction diameter (0.01+/-0.13 mm versus 0.01+/-0.11 mm, respectively), expressed as means per patient. On the basis of coronary segment, mean percent stenosis of all lesions showed a tendency to decrease; only in the apheresis group more minor lesions disappeared in comparison to the medication group. On bicycle exercise tests, the time to 0.1 mV ST-segment depression increased significantly by 39% and the maximum level of ST depression decreased significantly by 0.07 mV in the apheresis group versus no changes in the medication group.
Two years of lipid lowering both with medication alone or LDL-apheresis with medication showed angiographic arrest of the progression of coronary artery disease. However, more aggressive treatment induced functional improvement, which may precede anatomic changes.
强化降脂可能延缓冠状动脉粥样硬化的进展。低密度脂蛋白清除术有潜力将低密度脂蛋白胆固醇降至极低水平。为评估通过低密度脂蛋白清除术进行更积极降脂的效果,我们对患有高胆固醇血症和严重冠状动脉粥样硬化的男性开展了一项随机研究。
42名男性接受了为期2年的治疗,其中一组每两周进行一次低密度脂蛋白清除术并同时服药,另一组仅服药。两组均每天服用40毫克辛伐他汀。清除术组和药物治疗组的基线(均值±标准差)低密度脂蛋白胆固醇分别为7.8±1.9毫摩尔/升和7.9±2.3毫摩尔/升。低密度脂蛋白胆固醇的平均降幅分别为63%(降至3.0毫摩尔/升)和47%(降至4.1毫摩尔/升)。主要的冠状动脉造影定量终点是平均节段直径和最小阻塞直径的变化。清除术组和药物治疗组在平均节段直径(分别为-0.01±0.16毫米和0.03±0.16毫米)或最小阻塞直径(分别为0.01±0.13毫米和0.01±0.11毫米)方面未发现差异,以每位患者的均值表示。基于冠状动脉节段,所有病变的平均狭窄百分比呈下降趋势;与药物治疗组相比,仅清除术组更多的轻度病变消失。在自行车运动试验中,清除术组达到0.1毫伏ST段压低的时间显著增加了39%,ST段压低的最大程度显著降低了0.07毫伏,而药物治疗组无变化。
单独药物降脂或药物联合低密度脂蛋白清除术进行两年的降脂治疗均显示冠状动脉疾病进展在血管造影上得到遏制。然而,更积极的治疗可诱导功能改善,这可能先于解剖学改变。